A medication already reshaping how medicine approaches obesity and diabetes has revealed an unexpected affinity for the lungs: semaglutide, the active compound in Ozempic and Wegovy, is associated with roughly 40% fewer asthma attacks among those who take it. The finding, which extends to COPD as well, suggests that GLP-1 agonists may be quietly rewriting their own story — from metabolic drugs to something with a broader claim on human health. Science is now left to ask not only what this drug does, but why, and for whom.